Systematic review of pharmacogenetic testing for predicting clinical benefit to anti-EGFR therapy in metastatic colorectal cancer.
about
Comparative effectiveness research in cancer genomics and precision medicine: current landscape and future prospects.Does KRAS testing in metastatic colorectal cancer impact overall survival? A comparative effectiveness study in a population-based sample.Changes of TCR repertoire diversity in colorectal cancer after Erbitux (cetuximab) in combination with chemotherapyChanges in colorectal carcinoma genomes under anti-EGFR therapy identified by whole-genome plasma DNA sequencing.Cost-effectiveness analysis of screening for KRAS and BRAF mutations in metastatic colorectal cancer.Targeted therapies in colorectal cancer-an integrative view by PPPMMLH1-silenced and non-silenced subgroups of hypermutated colorectal carcinomas have distinct mutational landscapes.Improving the efficiency and relevance of evidence-based recommendations in the era of whole-genome sequencing: an EGAPP methods update.Molecular genetics of testicular germ cell tumors.Current clinical development of PI3K pathway inhibitors in glioblastoma.Rare Though Not Mutually Exclusive: A Report of Three Cases of Concomitant KRAS and BRAF Mutation and a Review of the Literature.Molecular Biomarkers for the Evaluation of Colorectal Cancer: Guideline From the American Society for Clinical Pathology, College of American Pathologists, Association for Molecular Pathology, and American Society of Clinical Oncology.K-RAS and N-RAS mutations in testicular germ cell tumors.Potential clinical significance of plasma-based KRAS mutation analysis using the COLD-PCR/TaqMan(®) -MGB probe genotyping method.
P2860
Q30412048-FCAFDF14-06D0-437B-A5A2-72C4C9853CEBQ33553166-407DFDCF-C0AC-4943-B4B6-E3401773D1E8Q34705000-00934A85-E25F-43F5-9531-E4D58F5E01E0Q35133788-C6050CA4-007D-4F58-9CA0-2B30F54550E2Q36444723-ACB4C451-695F-4EA5-8AD2-9C8EBFFB6187Q36646911-8CBA0449-1685-4F8F-B799-E88A2AFF5BB4Q37588178-4451CA2B-1165-4AEB-8389-5443CE18B807Q37598607-8E0C0CE4-1656-4DF6-B76A-CFBD201A1041Q37995190-9A06FAA0-6FCD-43FC-B955-0B20A2364B9DQ38012438-6F76B5B2-A2ED-48A8-88DA-93AED048C33FQ38097428-1281AAF1-1536-4247-ADF4-E26602634734Q40341349-1BB5F7C4-5F6D-4537-AA47-EBBD33ECC2F6Q42198222-2605455A-E9D4-42BA-B917-79C8E7E4E84DQ42571089-72288064-7548-4801-BA8F-B50ED8E5F5BC
P2860
Systematic review of pharmacogenetic testing for predicting clinical benefit to anti-EGFR therapy in metastatic colorectal cancer.
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on May 2011
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
Systematic review of pharmacog ...... metastatic colorectal cancer.
@en
Systematic review of pharmacog ...... metastatic colorectal cancer.
@nl
type
label
Systematic review of pharmacog ...... metastatic colorectal cancer.
@en
Systematic review of pharmacog ...... metastatic colorectal cancer.
@nl
prefLabel
Systematic review of pharmacog ...... metastatic colorectal cancer.
@en
Systematic review of pharmacog ...... metastatic colorectal cancer.
@nl
P2093
P2860
P1476
Systematic review of pharmacog ...... n metastatic colorectal cancer
@en
P2093
Caitlyn A Senger
Elizabeth M Webber
Evelyn P Whitlock
Jennifer S Lin
Rebecca S Holmes
P2860
P304
P577
2011-05-01T00:00:00Z